Why the study?
Does nonsurgical septal reduction improve symptoms in patients with hypertrophic cardiomyopathy inadequately controlled with standard medical therapy?
Does nonsurgical septal reduction improve symptoms in patients with hypertrophic cardiomyopathy inadequately controlled with standard medical therapy?
Nonsurgical septal reduction is proposed as a treatment for symptomatic hypertrophic cardiomyopathy refractory to standard medical therapy.
Answers are grounded in this paper and cite their sources.
May warrant consideration in refractory hypertrophic cardiomyopathy; leaves open need for randomized confirmation of benefit.
Nonsurgical septal reduction has been proposed as a means of treating patients with hypertrophic cardiomyopathy whose symptoms of exercise limitation by chest pain or breathlessness are inadequately controlled with standard medical therapy (i.e., beta blockers, calcium antagonists, or even DDD pacing).
No takes yet. Share an insight, caveat, or question.
Henein et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: